Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics

Enanta Pharmaceuticals, Inc. (ENTA): $56.49

-0.60 (-1.05%)

POWR Rating

Component Grades













Add ENTA to Watchlist
Sign Up

Industry: Biotech


of 459

in industry


  • Value is the dimension where ENTA ranks best; there it ranks ahead of 76.44% of US stocks.
  • ENTA's strongest trending metric is Stability; it's been moving down over the last 163 days.
  • ENTA ranks lowest in Momentum; there it ranks in the 9th percentile.

ENTA Stock Summary

  • Of note is the ratio of Enanta Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 6.46% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Enanta Pharmaceuticals Inc is higher than it is for about just 7.64% of US stocks.
  • ENTA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 7.71% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Enanta Pharmaceuticals Inc, a group of peers worth examining would be PTGX, XENE, SGMO, NRIX, and RVMD.
  • Visit ENTA's SEC page to see the company's official filings. To visit the company's web site, go to www.enanta.com.

ENTA Valuation Summary

  • In comparison to the median Healthcare stock, ENTA's price/sales ratio is 213.16% higher, now standing at 11.9.
  • Over the past 103 months, ENTA's price/sales ratio has gone up 7.7.
  • Over the past 103 months, ENTA's EV/EBIT ratio has gone down 18.3.

Below are key valuation metrics over time for ENTA.

Stock Date P/S P/B P/E EV/EBIT
ENTA 2021-08-31 11.9 2.8 -13.8 -12.5
ENTA 2021-08-30 11.8 2.7 -13.7 -12.4
ENTA 2021-08-27 11.7 2.7 -13.5 -12.2
ENTA 2021-08-26 11.2 2.6 -13.0 -11.8
ENTA 2021-08-25 11.1 2.6 -12.9 -11.6
ENTA 2021-08-24 11.0 2.6 -12.8 -11.6

ENTA Growth Metrics

    Its year over year revenue growth rate is now at -46.46%.
  • Its year over year cash and equivalents growth rate is now at 3.72%.
  • The 2 year cash and equivalents growth rate now stands at 10.98%.
ENTA's revenue has moved down $5,740,000 over the prior 49 months.

The table below shows ENTA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 97.074 -69.996 -78.996
2021-06-30 97.13 -64.436 -83.738
2021-03-31 94.159 -39.418 -73.979
2020-12-31 101.646 -20.165 -57.939
2020-09-30 122.473 7.088 -36.168
2020-06-30 150.155 31.094 2.364

ENTA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENTA has a Quality Grade of C, ranking ahead of 57.4% of graded US stocks.
  • ENTA's asset turnover comes in at 0.206 -- ranking 196th of 682 Pharmaceutical Products stocks.
  • GILD, ALT, and RDUS are the stocks whose asset turnover ratios are most correlated with ENTA.

The table below shows ENTA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.206 1 -0.234
2021-03-31 0.193 1 -0.207
2020-12-31 0.204 1 -0.157
2020-09-30 0.242 1 -0.083
2020-06-30 0.296 1 -0.048
2020-03-31 0.354 1 0.017

ENTA Price Target

For more insight on analysts targets of ENTA, see our ENTA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $65.33 Average Broker Recommendation 1.7 (Moderate Buy)

ENTA Stock Price Chart Interactive Chart >

Price chart for ENTA

ENTA Price/Volume Stats

Current price $56.49 52-week high $102.00
Prev. close $57.09 52-week low $40.37
Day low $56.44 Volume 226,900
Day high $58.70 Avg. volume 215,464
50-day MA $76.27 Dividend yield N/A
200-day MA $59.70 Market Cap 1.15B

Enanta Pharmaceuticals, Inc. (ENTA) Company Bio

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.

ENTA Latest News Stream

Event/Time News Detail
Loading, please wait...

ENTA Latest Social Stream

Loading social stream, please wait...

View Full ENTA Social Stream

Latest ENTA News From Around the Web

Below are the latest news stories about Enanta Pharmaceuticals Inc that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

Enanta under pressure after SVB Leerink slashed price target

The shares of Enanta Pharmaceuticals (ENTA -7.2%) dropped for the third straight session to reach over a three-month low after SVB Leerink cut its price target, highlighting the concerns on the biotech’s pipeline. Last week, the Watertown, Massachusetts-based Enanta (NASDAQ:ENTA) announced its outlook for the year ahead of its presentation...

Seeking Alpha | January 13, 2022

Enanta Pharmaceuticals rises on pipeline updates for 2022

Enanta Pharmaceuticals (ENTA +3.3%) provided updates on its pipeline and said President and CEO Jay Luly will shed light on the virology programs and plans for 2022 at the 40th Annual J.P. Morgan Healthcare conference on Jan. 11. EDP-938 is being evaluated in three ongoing phase 2 trials: RSVP, RSVPEDs and RSVTx. The...

Seeking Alpha | January 6, 2022

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., January 06, 2022--Enanta Pharmaceuticals to Provide Updates on its R&D Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

Yahoo | January 6, 2022

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., January 04, 2022--Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Yahoo | January 4, 2022

Contrasting Mallinckrodt (OTCMKTS:MNKKQ) and Enanta Pharmaceuticals (NASDAQ:ENTA)

Mallinckrodt (OTCMKTS:MNKKQ) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation. Analyst Ratings This is a summary of recent recommendations for Mallinckrodt and Enanta Pharmaceuticals, as reported []

Dakota Financial News | December 18, 2021

Read More 'ENTA' Stories Here

ENTA Price Returns

1-mo N/A
3-mo -25.35%
6-mo 36.25%
1-year 18.50%
3-year -25.19%
5-year 70.97%
YTD -24.46%
2021 77.62%
2020 -31.85%
2019 -12.78%
2018 20.71%
2017 75.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.2628 seconds.